Want to see AKTS full AI Analyst Report?
AKTS Stock Chart & Stats
$20.25
--
Market closed
$20.25
--
Day’s Range― - ―
52-Week Range$14.72 - $34.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.38B
Enterprise Value$896.56M
Total Cash (Recent Filing)$538.48M
Total Debt (Recent Filing)$11.58M
Price to Earnings (P/E)―
Beta2.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,404,617
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue175.90
Enterprise Value/Gross Profit201.70
Enterprise Value/Ebitda-27.92
Forecast
1Y Price Target
$35.50Price Target Upside75.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendA ~596% revenue increase in 2025 signals accelerating commercial traction or milestone-driven sales. If this top-line ramp is sustained, it supports operating leverage, improves economies of scale, and reduces the relative burden of fixed R&D/SG&A costs over the next several quarters.
Gross Margin StrengthReported strong gross margins indicate favorable unit economics and pricing power in the core offering. Durable higher gross margins provide structural room to fund R&D and SG&A while retaining a path to sustainable operating margins as revenue scales over the medium term.
Modest Absolute DebtTotal debt of roughly $11.5M is modest in absolute terms, lowering immediate solvency pressure. Lower financial leverage preserves flexibility to pursue equity raises, partnerships, or milestone financings without the heavier constraints faced by highly leveraged peers.
Bears Say
Negative And Deteriorating EquityEquity deterioration to approximately -$146.1M from -$87.8M reflects cumulative losses and eroded balance sheet cushion. Persistent negative equity increases dilution and financing risk, complicates partner or lender negotiations, and undermines long-term solvency perception.
Return To Heavy Cash BurnThe swing to ~-$64.1M operating cash flow and ~-$73.7M free cash flow in 2025 reverses prior positive cash generation. Such volatile and large cash burn necessitates frequent external funding, raising execution risk and potentially forcing program delays or unfavorable financing terms over months.
Large Net LossesA ~$63.7M net loss on ~$6.5M revenue demonstrates deep unprofitability and high operating leverage. Sustained large losses imply a long path to breakeven, likely ongoing dilution, and limited ability to self-fund growth or scale without recurring capital raises.
Aktis Oncology, Inc. News
AKTS FAQ
What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $1.38B.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aktis Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,404,617 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Currently, no hedge funds are holding shares in AKTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aktis Oncology, Inc. Stock Smart Score
Company Description
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
AKTS Stock 12 Month Forecast
Average Price Target
$35.50
▲(75.31% Upside)
Iovance Biotherapeutics
―
Zymeworks
―
Oric Pharmaceuticals
―
Immunocore Holdings
―
Nanobiotix
―
Ownership Overview
47.63% Insiders
4.33% Mutual Funds
0.08% Other Institutional Investors
44.14% Public Companies and
Individual Investors